Asia Pacific Botulinum Toxin Market Size, Share & Industry Trends Analysis Report By Product, By Application (Therapeutic and Aesthetic), By End User (Hospitals, Dermatology Clinics and Spas & Cosmetic Centers, By Country and Growth Forecast, 2022 - 2028

The Asia Pacific Botulinum Toxin Market is expected to witness market growth of 11.4% CAGR during the forecast period (2022-2028).

All cholinergic postganglionic sympathetic and parasympathetic neurons are affected by the toxin's inhibition of acetylcholine release. Due to this, there has been a number of studies on its usage as a therapy for aberrant gland activity or overactive smooth muscles, such as in achalasia. This has sparked interest in using it to treat aberrant gland activity or overactive smooth muscles, such as in achalasia. The toxin takes between 24 to 72 hours to start working, which corresponds to how long it takes to stop the synaptosomal process. In extremely exceptional situations, some people could need up to five days to observe the full effect.

A variety of conditions characterized by excessive muscular movement are treated with botulinum toxin, including cerebral palsy following a stroke, post-spinal cord injuries spasticity, and spasms of the head, neck, vagina, eyelid, limbs, jaw, and vocal cords. Similar to how it is used to relax tensed jaw muscles, esophageal muscles, bladder muscles, lower urinary tract muscles, and anus muscles that might aggravate the anal fissure. The botulinum toxin seems to work for persistent overactive bladder.

In India, chronic daily headaches, or CDH, are still mostly unstudied. There are many misconceptions, numerous unneeded investigations, and unsuitable therapies recommended. Headaches that occur more than 15 days a month for more than three months are referred to as CDH or chronic migraine. In a study of the National Library of Medicines, 849 instances (49.6% of all main headaches) were observed in India during the course of two years. This is becoming a subject of concern in the region.

The China market dominated the Asia Pacific Botulinum Toxin Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $845.6 Million by 2028.The Japan market is estimated to grow a CAGR of 10.7% during (2022 - 2028). Additionally, The India market is expected to experience a CAGR of 12% during (2022 - 2028).

Based on Product, the market is segmented into Type A and Type B. Based on Application, the market is segmented into Therapeutic and Aesthetic. Based on End User, the market is segmented into Hospitals, Dermatology Clinics and Spas & Cosmetic Centers. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Evolus, Inc. (Alphaeon Corporation), Merz Pharma GmbH & Co. KGaA, AbbVie, Inc., Ipsen Pharma, Galderma S.A., USWM, LLC, and Metabiologics, Inc. (Object Pharma).

Scope of the Study

Market Segments Covered in the Report:

By Product

• Type A
• Type B

By Application

• Therapeutic
• Aesthetic

By End User

• Hospitals
• Dermatology Clinics
• Spas & Cosmetic Centers

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

• Evolus, Inc. (Alphaeon Corporation)
• Merz Pharma GmbH & Co. KGaA
• AbbVie, Inc.
• Ipsen Pharma
• Galderma S.A.
• USWM, LLC
• Metabiologics, Inc. (Object Pharma)

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of Market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free